Goal 2: Reduce Human Disease

Submitted by (@dtriulzi)

Development of Optimally Hemostatic, Systemically Safe, Platelet Mimetics or Substitutes

What are the knowledge and technological gaps in production, evaluation and clinical translation of donor-independent platelets for transfusions? Specific questions include: a) How can stem or progenitor cells be expanded to maximize platelet production?; b) What are the hemostatically relevant design and function requirements and evaluation metrics for ideal/optimal “biologic” and “synthetic” platelets? c) What preclinical ...more »

Voting

20 net votes
38 up votes
18 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@cjoseph)

Consequences of ABO or Rh Type Specific versus Non-Type Specific Platelet Transfusions

What are the consequences, clinically and immunologically, of ABO or Rh type specific vs. non-type specific platelet transfusions? There is widely varying practice as to ABO and Rh matching of platelets for transfusion. Most studies demonstrate that use of ABO unmatched (non-identical) platelets are associated with increased 1) platelet refractoriness (small randomized trials), 2) red cell transfusion needs and hemolysis, ...more »

Voting

-4 net votes
25 up votes
29 down votes
Active